-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Cullinan Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga·02/02/2026 14:33:08
Listen to the news
Guggenheim analyst Brad Canino initiates coverage on Cullinan Therapeutics (NASDAQ:CGEM) with a Buy rating and announces Price Target of $30.